IDH1R132H is intrinsically tumor-suppressive but functionally attenuated by the glutamate-rich cerebral environment
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1278 views | HTML 1889 views | ?
Patricia D.B. Tiburcio1,2,*, Bing Xiao1,3,*, Yi Chai1,3, Sydney Asper1, Sheryl R. Tripp4, David L. Gillespie1, Randy L. Jensen1 and L. Eric Huang1,2
1Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, Salt Lake City, Utah, USA
2Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA
3Department of Neurosurgery, Nanchang University Second Affiliated Hospital, Nanchang, Jiangxi, People’s Republic of China
4ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, Utah, USA
*These authors contributed equally to this work
L. Eric Huang, email: [email protected]
Keywords: glioma; glutamate; isocitrate dehydrogenase 1; mouse model; RCAS
Received: September 13, 2018 Accepted: September 21, 2018 Published: October 12, 2018
Recurrent heterozygous mutation of isocitrate dehydrogenase 1 gene (IDH1), predominantly resulting in histidine substitution at arginine 132, was first identified in glioma. The biological significance of IDH1R132H, however, has been controversial, and its prevalent association with glioma remains enigmatic. Although recent studies indicate that IDH1R132H is nonessential to tumor growth or even anti-tumor growth, whether IDH1R132H initiates gliomagenesis remains obscure. In this study, we report that IDH1R132H is intrinsically tumor-suppressive but the activity can be attenuated by glutamate—the cerebral neurotransmitter. We observed that IDH1R132H was highly suppressive of subcutaneous tumor growth driven by platelet-derived growth factor B (PDGFB), but IDH1R132H tumor growth and glioma penetrance were virtually indistinguishable from those of IDH1-wildtype tumors in orthotopic models. In vitro, addition of glutamate compromised IDH1R132H inhibition of neurosphere genesis, indicating glutamate promotion of oncogenic dominance. Furthermore, we observed that IDH1R132H expression was markedly decreased in tumors but became more permissible upon the deletion of tumor-suppressor gene Cdkn2a. To provide direct evidence for the opposing effect of IDH1R132H on PDGFB-driven glioma development, we explored tandem expression of the two molecules from a single transcript to preclude selection against IDH1R132H expression. Our results demonstrate that when juxtaposed with oncogenic PDGFB, IDH1R132H overrides the oncogenic activity and obliterates neurosphere genesis and gliomagenesis even in the glutamate-rich microenvironment. We propose therefore that IDH1R132H is intrinsically suppressive of glioma initiation and growth but such tumor-suppressive activity is compromised by the glutamate-rich cerebral cortex, thereby offering a unifying hypothesis for the perplexing role of IDH1R132H in glioma initiation and growth.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.